Aura Biosciences (NASDAQ:AURA) Posts Earnings Results

Aura Biosciences (NASDAQ:AURA) posted its quarterly earnings data on Monday. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.09), Zacks reports.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $7.00 on Tuesday. The stock has a market capitalization of $349.66 million, a PE ratio of -4.05 and a beta of 0.30. Aura Biosciences has a fifty-two week low of $6.33 and a fifty-two week high of $12.38. The company has a fifty day moving average of $7.65 and a two-hundred day moving average of $8.66.

Insider Buying and Selling

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 23,045 shares of company stock worth $177,242 in the last 90 days. Insiders own 5.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research note on Monday. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Aura Biosciences currently has a consensus rating of “Buy” and an average target price of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.